Who makes SHR-A1811and 5-FU?

SHR-A1811and 5-FU is developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd..

What development phase is SHR-A1811and 5-FU in?

SHR-A1811and 5-FU is in Phase 2.

Last reviewed 2026-04-19 · How we verify

SHR-A1811and 5-FU

Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Phase 2 active Small molecule

At a glance

Generic name	SHR-A1811and 5-FU
Sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SHR-A1811and 5-FU CI brief — competitive landscape report
SHR-A1811and 5-FU updates RSS · CI watch RSS
Suzhou Suncadia Biopharmaceuticals Co., Ltd. portfolio CI